SLCO1B1 and metabolic dysfunction-associated steatotic liver disease: As a proof of concept, OATP1B1 zonal abundance data derived from our study were incorporated into a physiologically based multicompartment liver model to successfully recapture concentration-time profiles of a complex transporter-mediated drug-drug interaction scenario involving repaglinide and rifampin in a NDL population.50 Our current dataset would allow for further simulation of drug response and toxicity in a physiologically based pharmacokinetic/pharmacodynamic or quantitative systems toxicology framework for both NDL and NAFLD patient populations.